Tag Archives: Zolgensma

Novartis’ SMA gene therapy Zolgensma could struggle to hit blockbuster territory: report

Despite an ongoing soap opera surrounding Zolgensma, Novartis’ gene therapy for spinal muscular atrophy (SMA), Wall Street analysts are optimistic about the product overall, with some estimating peak sales north of $ 2 billion a year. JPMorgan analysts surveyed 26 physicians who treat SMA and came to a vastly different conclusion: Concerns about the efficacy of… Read More »

Senator Grassley seeks info on Novartis’s Zolgensma data issues

FILE PHOTO: U.S. Senator Chuck Grassley (R-IA) speaks to reporters on his way from the Senate floor after a vote at the U.S. Capitol in Washington, U.S. May 14, 2019. REUTERS/Jonathan Ernst/File Photo (Reuters) – U.S. Senate Finance Committee Chairman Chuck Grassley has asked Swiss drugmaker Novartis AG to provide details on data manipulation related… Read More »